Cowen Healthcare Conference Bill Sibold, Global Franchise Head

Multiple Sclerosis, Oncology & Immunology, Sanofi Genzyme Boston – March 7, 2017

2

Forward Looking Statements

This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2016. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

3

Agenda

2016 Financial performance

Leading position in Rare Diseases

Rapidly growing Multiple Sclerosis portfolio

New Sanofi Genzyme Immunology franchise

Re-building a competitive position in Oncology

Company Sales(1) Business EPS(2)

2016 Financial Performance Stronger than Initial Expectations

€33,821m(3)

FY 2015 FY 2016

€34,060m

4

(1) FY 2015 Company Sales restated to exclude Animal Health Business (2) FY 2015 and FY 2016 Business EPS includes the contribution from Animal Health (3) FY 2016 Company Sales were €36,529m (+1.8% at CER) including Animal Health (previously referred to as “Aggregate Sales”) (4) Evolution at Constant Exchange Rates (CER) (5) On a reported basis, FY 2016 sales were down -0.7% and Business EPS was up +0.7%

+1.2% at CER(4,5)

FY 2016

€5.68

FY 2015

€5.64 +4.1% at CER(4,5)

5

Growth at CER

2016 Sales Increase Driven by Double-Digit Growth at Sanofi Genzyme

2016 Sales by Global Business Unit

Company Sales €33,821m +1.2%

€6,397m Diabetes & Cardiovascular -2.0%

€5,019m Sanofi Genzyme (Specialty Care) +17.3%

€4,577m Sanofi Pasteur (Vaccines) +8.8%

€14,498m General Medicines & Emerging Markets -3.3% (3,4,5)

(6)

(1)

(2)

(1)

€3,330m Consumer Healthcare -1.6%

(1) Does not include Emerging Markets sales (2) Reflecting reclassification of VaxServe from Sales to Other

revenues from Jan 1, 2016 (3) Includes Emerging Markets sales for Diabetes &

Cardiovascular and Specialty Care (4) Emerging Markets: World excluding U.S., Canada, Western &

Eastern Europe (except Eurasia), Japan, South Korea, Australia, New Zealand and Puerto Rico

(5) Excluding global Consumer Healthcare sales (6) Consumer Healthcare expected to become a GBU in 2017 and

includes sales in Emerging Markets Pictures by Freepik

6

● Speciality Care franchises represent around 18% of Sanofi sales(1)

● Proven ability to execute in specialized disease areas

● Leading position in Rare Diseases

● Rapidly growing Multiple Sclerosis franchise

● Re-building a competitive position in Oncology

● New Sanofi Genzyme Immunology franchise

● Dupixent® and Kevzara® U.S. launch preparation activities ongoing(2)

(1) Calculated using FY 2016 sales (2) Dupixent® and Kevzara® are investigational agents under clinical development and their safety and

efficacy have not been fully evaluated by any Regulatory Authority except in Canada for Kevzara®

2015 2016

Rare Diseases Multiple Sclerosis Oncology

Global Specialty Care Franchise Sales

Rare Disease and Multiple Sclerosis Driving Growth in Specialty Care

€5,950m

€5,168m

€2,550m

€2,777m +11.7% at CER

€1,720m +56.1% at CER €1,114m

€1,504m €1,453m -2.2% at CER

+17.2% at CER

7

Agenda

2016 Financial performance

Leading position in Rare Diseases

Rapidly growing Multiple Sclerosis portfolio

New Sanofi Genzyme Immunology franchise

Re-building a competitive position in Oncology

2014 2015 2016

Other

Rare Diseases: Strong New Patient Accrual and Emerging Markets Growth Sustained in 2016

Rare Diseases Sales €2,777m

+11.7% at CER

€2,550m

€2,137m

8

● Gaucher franchise grew +9.6% to €854m

● Promote use of proven screening protocols among hematologists

● Optimize launch of Cerdelga®

● EM sales up +27.1% to €239m

● Fabry franchise grew +14.7% to €674m ● Focus primarily on nephrologists and family

tree mapping to drive patient identification ● EM sales up +25.4% to €68m

● Pompe franchise grew +13.5% to €725m ● Drive testing of high risk patients in neurology

and neuromuscular specialty areas ● EM sales up +20.2% to €102m

&

9

Agenda

2016 Financial performance

Leading position in Rare Diseases

Rapidly growing Multiple Sclerosis portfolio

New Sanofi Genzyme Immunology franchise

Re-building a competitive position in Oncology

10

2014 2015 2016

€1,720m +56.1% at CER

€425m +79.0% at CER

€467m

● Fastest growing oral relapsing MS product with sales up +49.7% in 2016(1)

● Number 1 switched to DMT in the U.S.(2)

● Increasing breadth and depth of prescribing with sales up +79.0% in 2016

10

Multiple Sclerosis Sales

€1,295m +49.7% at CER

Multiple Sclerosis Franchise Continued to Deliver Strong Growth in 2016

10

€1,114m

DMT: Disease Modifying Therapy (1) Sanofi Genzyme market research (2) IMS NPA Market Dynamics

11

Attractive Efficacy, Safety, Tolerability and Once-Daily Oral Dosing Profile(1)

● Approved in more than 70 countries with ~67,000 patients currently treated worldwide

● Growing and positive experience among patients and neurologists(2)

● Established safety and tolerability with over 10 years of clinical trial data(3)

● Only oral RMS treatment to: ● Significantly reduce the risk of disability

progression in two Phase III studies(4)

● Studied in newly diagnosed RMS patients, 72% of whom remained relapse free(5)

RMS: relapsing multiple sclerosis (1) AUBAGIO® (teriflunomide) is effective across key measures of disease activity: sustained disability progression (14 mg only), annualized relapse rate,

and MRI activity. Common side effects with AUBAGIO led to treatment discontinuation rates ≤3.3% in clinical trials. (2) Sanofi Genzyme market research (3) The TEMSO Extension Study: Kappos L et al. ECTRIMS 2015. P1099, O’Connor P et al. ECTRIMS 2015. P555. (4) TEMSO study: O’Connor P et al. N Engl J Med. 2011;365:1293-1303; TOWER study: Confavreux C et al. Lancet Neurol. 2014;13:247-256. (5) TOPIC study: Miller AE, et al. Lancet Neurol. 2014;13:977-986.

(1) IMS NPA/NSP, January 2017 (2) Oral category includes Aubagio®, Gilenya®, Tecfidera®, laquinimod, 2nd Gen S1Ps

Intravenous category includes Tysabri®, Lemtrada®, ocrelizumab, daclizumab Injectable category includes Avonex®, Betaseron/Betaferon®, Copaxone®, Rebif®, Extavia®, Plegridy™

(3) IMS NPA, week ending February 10th, 2017 12

Making Steady TRx Share Gains

Aubagio® is the Fastest Growing Oral Relapsing MS Product(2)

U.S. TRx Share

Oral Therapies Have Gained Significant Market Share(1)

U.S. TRx Share

7% 17%

30% 34% 37%

86% 74% 60% 55% 52%

6% 9% 10% 10% 11%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

2012 2013 2014 2015 2016

Injectables Intravenous Orals

Tecfidera®

21.2%

0%

5%

10%

15%

20%

25%

Feb-15 Aug-15 Feb-16 Aug-16 Feb-17

Gilenya®

11.4%

9.1%

13

Potential to Change Relapsing MS Treatment with an Established Benefit-Risk Profile(1,2)

● Approved in more than 60 countries with over 12,000 patients treated commercially worldwide

● Over 12 years of clinical trial data and 8,600 patient-years of follow up

● Only relapsing MS therapy which offers efficacy in the absence of chronic treatment(3)

● No retreatment with Lemtrada® after the initial 2 courses in the core studies for a majority of patients through Year 6(4)

● Draft ICER report finds Lemtrada® represents best long-term cost-effectiveness(5)

DMTs: Disease-Modifying Therapies (1) The most common side effects of Lemtrada® are rash, headache,

thyroid disorder, pyrexia, nasopharyngitis, nausea, urinary tract infection, fatigue, insomnia, upper respiratory tract infection, herpes viral infection, urticaria, pruritus, fungal infection, arthralgia, pain in extremity, back pain, diarrhea, sinusitis, oropharyngeal pain, paresthesia, dizziness, abdominal pain, flushing, and vomiting. Other serious side effects associated with Lemtrada® include autoimmune thyroid disease, autoimmune cytopenias, infections and pneumonitis.

(2) Label includes a boxed warning noting a risk of serious, sometimes fatal autoimmune conditions, serious and life threatening infusion reactions

and noting Lemtrada® may cause an increased risk of malignancies including thyroid cancer, melanoma and lymphoproliferative disorders. Lemtrada® is contraindicated in patients with HlV infection.

(3) Sustained improvements in relapse, disability, and MRI over 5 years in active RRMS in the absence of continuous dosing demonstrated in CARE-MS I and II extension studies

(4) The percentages of those not receiving retreatment with Lemtrada were: 64% from CARE-MS I and 55% from CARE-MS II.

(5) Institute for Clinical and Economic Review (ICER) Evidence Report on Disease-Modifying Therapies for Multiple Sclerosis, including daclizumab and ocrelizumab (January 2016)

14

Agenda

2016 Financial performance

Leading position in Rare Diseases

Rapidly growing Multiple Sclerosis portfolio

New Sanofi Genzyme Immunology franchise

Re-building a competitive position in Oncology

Growth in Rheumatoid Arthritis Market Expected to be Driven by Non-TNFα Inhibitor Class

15

$21bn

Others(3) IL-6 inhibitors Anti-TNFα

$19bn ~$20bn ~$22bn

2015 2017 2022

(1) DRG (G7), December 2016 (2) Forecasts include generic, branded and biosimilar products (3) Others includes DMARDs, CD-20 and T-cell agents, JAK inhibitors and others

CAGR -0.8%

CAGR +7%

CAGR +7%

Market Expected to Grow ~2% 2017-2022 CAGR with IL-6 Inhibitors Projected to Grow ~7%(1,2)

Non-TNFα MOAs Now Included in RA First Line Biologic Recommendations Following DMARD Failure

● TNFα inhibitor or non-TNFα biologic, either in combination with MTX or as monotherapy, recommended as first line biologic following DMARD failure(1)

● TNFα inhibitor, Orencia® and Actemra® recommended as first line biologic in combination or as monotherapy if MTX/DMARD are not tolerated(2)

● Rituxan® and Xeljanz® recommended following first line biologics

2015 ACR Recommendation 2013 EULAR Recommendation

Use of Non-TNFα MOA Products is Increasing and is Over 50% Beyond First Line Biologics(3)

(TRx Market Share)

RA: rheumatoid arthritis; MTX: Methotrexate; DMARD: Disease-Modifying Anti-Rheumatic Drugs; MoA: Mechanism of Action Rituxan® (rituximab) and Actemra® (tocilizumab) are marketed by Roche; Orencia® (abatacept) is marketed by BMS; Xeljanz® (tofacitinib) is marketed by Pfizer

(1) Based on moderate to very low evidence (2) When prognostically unfavorable factors present; Under certain

conditions, Rituxan® is recommended as first line biologic (3) Source: IPSOS 16

1st line biologic 2nd line biologic 3rd line biologic 1st line biologic 2nd line biologic 3rd line biologic

81% 44%

19%

15% 56%

81% 84%

49% 16%

8% 51%

84% Non-TNFα MOA

Anti-TNFα

New RA Market Trends: Anti-TNFα Cycling Declining with More Switching to Non-TNFα MOAs and Monotherapy

17

MTX – Methotrexate DMARD – Disease-Modifying Anti-Rheumatic Drugs MoA – Mechanism of Action Note: Biologics penetration varies somewhat by region Source: IPSOS data 2014 – Decision Resources 2014

Patient Flow (% of patients)

Other biologic

Anti-TNFα

Anti-TNFα

Other biologic

Combination Therapy

(Add to MTX) ~50%

~50%

IL-6R

2nd Biologic (change MoA)

Other Biologic

2nd Anti-TNFα Anti-TNFα

Cycling

DMARD-IR (G7) New Trends

● Anti-TNFα in 1st line decreasing

● Anti-TNFα cycling declining with more evidence showing improved efficacy from switching to a non-TNFα MOA

● Increasing number of patients on monotherapy and guidelines supporting IL6 as monotherapy

● Patient preference for SC administration

Monotherapy

Other Biologic

Anti-TNFα

Anti-TNFα

Other Biologic

Recently Received First Approval in Canada and U.S. Launch Preparation Ongoing

18

Kevzara is developed in collaboration with Regeneron Pharmaceuticals, Inc. Kevzara is an investigational agent under clinical development and its safety and efficacy has not been fully evaluated by any Regulatory Authority except in Canada (1) Brand name has been conditionally approved

(2) Most frequently reported Treatment Emergent Adverse Events include serious infections, injection site erythema and neutropenia (3) Based on one head to head superiority study comparing sarilumab and Humira in improving signs and symptoms of RA in adults (MONARCH).

A second confirmatory study has not been conducted. Neutropenia, which was not associated with infections, was more common with sarilumab than Humira®. Not included in the initial BLA filed with FDA; Humira® (adalimumab) is an AbbVie brand

(4) Subject to successful FDA pre-license inspection related to Dupixent

● IL-6 plays key roles in the local joint symptoms and systemic manifestations of rheumatoid arthritis (RA)

● Positive Phase 3 efficacy/safety data in methotrexate-inadequate responder (IR) and difficult-to-treat TNF-IR populations(2)

● Positive Kevzara® monotherapy efficacy data compared to Humira® monotherapy(3)

● Preferred SC administration with less frequent Q2W dosing

(1)

Expect re-submission of U.S. BLA in Q1 2017(4)

19

A Pipeline in a Product - Clinical Studies in Multiple Indications Underway

Nasal polyposis Phase 3 started in Q4 2016

Asthma Phase 3 fully enrolled and U.S. submission

expected in Q4 2017

Atopic dermatitis (AD) Phase 3, March 29 FDA PDUFA Date Accepted for review by EMA in Dec 2016

Type 2, including Th-2 mediated diseases

DUPILUMAB

Eosinophilic esophagitis Ph 2 data exp. H2 17 Food allergy Phase 2 expected to start H2 17

Additional Indications

Pediatric expansion in AD(1) and Asthma Ph 3 studies in AD (age 6-11 and 12-17) and

Asthma (age 6-11) expected to start in 2017

(1) FDA Breakthrough designation for adults and pediatric moderate to severe atopic dermatitis

20

Potential First-in-Class Biologic for Adults with Uncontrolled Moderate to Severe AD

Atopic Dermatitis (AD)

● Characterized by intense itching and recurrent eczematous lesions

● Multifactorial etiology involving immune-mediated inflammation, genetic factors, and environmental triggers

● Although it often starts in infancy, it is also highly prevalent in adults

IGA 4 IGA 1

● BSA affected: 86.5% ● EASI score: 51.5 ● Pruritus NRS: 7 ● AD duration: 48 years

● BSA affected: 2.5% ● EASI score: 3.1 ● Pruritus NRS: 1.6

BLA accepted for priority review by the FDA with PDUFA date of March 29, 2017

®

Pictures from Phase 3 clinical trial provided for illustration purposes only to show how the clinical parameters above may correlate to the clinical presentation of a patient.(1)

Dupixent® is developed in collaboration with Regeneron Pharmaceuticals, Inc. Dupixent® is an investigational agent under clinical development and its safety and efficacy has not been fully evaluated by any Regulatory Authority IGA: Investigator Global Assessment BSA: Body Surface Area EASI: Eczema Area and Severity Index NRS: Numerical Rating Scale (1) Images are taken from one patient at baseline (left) and at 16 weeks (right). Results were not representative of all patients and individual results did

vary. In phase 3 clinical trials, the percentage of patients achieving an IGA score of 0 or 1 ranged from 36%-38%. Adverse events that were higher for Dupixent® vs placebo included injection site reactions and conjunctivitis; Photo used with permission

AD Sufferers Often Experience Severe, Persistent Itch

21

(1) Simpson EL et al, J Am Acad Dermatol. 2016;74(3):491-498 (2) Elman S et al. Br J Dermatol. 2010;162(3):587-593. (3) Charman CR et al. Arch Dermatol. 2004;140(12):1513-1519. (4) Yang Y et al. Eur J Health Econ. 2015;16:927-939.

‡Assessed using EuroQol (EQ-5D).(4)

Characteristics and Consequences of Itch in Moderate-to-Severe AD (N = 380 patients)(1)

†Assessed using the Patient-oriented Eczema Measure (POEM).(3) *Assessed using the 5-D pruritus scale.(2)

Severe

Frequent

Long-lasting

Pain

Disrupted sleep

experienced severe or unbearable itching* 61%

86% reported daily itch symptoms†

63% reported itching at least 12 hours a day*

77% reported moderate or extreme pain or discomfort‡

4.4 per week, on average, were interrupted by itching† nights

AD Treatment Guidelines Recommend Increasing Intensity of Therapy as Disease Severity Advances(1)

22

TCS: Topical Corticosteroids; TCI: Topical Calcineurin inhibitors Systemic therapy include oral corticosteroids and immunosuppressants (mostly used off-label, with the exception of cyclosporine, which is licensed for short-term treatment of severe refractory AD in European countries). (1) Akdis CA et al. Allergy. 2006;61:969-987 (2) Guidelines by the Practical Consensus Group EAACI+AAAAI. Japanese guidelines relatively similar (3) Eichenfield LF at al. J Am Dermatol. 2014;71:116-132 (4) Akhavan A et al. Semin Cutan Med Surg. 2008;27:151-155 (5) Grundmann SA et al, J Allergy (Cairo). 2012;2012:121797

Current AD Treatment Algorithm(2)

Antibiotic therapy used on frequent basis with recurrent infections (most Staphylococcus aureus)

Emollients, skin hydration

Low-mid potency TCS and/or TCI + Basic treatment

Mid-high potency TCS/TCI + Basic treatment

Systemic or UV therapy + Mid-high potency TCS/TCI

+ Basic treatment

antih

ista

min

es

mild

m

oder

ate

seve

re

Potential Limitations of Currently Available Therapies

● Topical corticosteroids (TCS): Current standard of care, can be effective, but not recommended for prolonged use(3)

● Immunosuppressants: The majority of systemic therapies are not FDA approved and are also not recommended for long term use due to potential, serious immunosuppressing side effects(4)

● Phototherapy (UV): Inconvenient and not available for all patients(5)

U.S. Launch Planning Focused on Patients with the Highest Unmet Medical Need

23

Physician Focus

Target physicians who treat AD patients and who have experience prescribing biologics

(i.e. Psoriasis)

Up to 7,000 doctors in the U.S.

Patient Focus

Moderate to severe AD patients intolerant to or

inadequate response to an existing therapy

(e.g. Topicals, Oral/systemic steroids, Immuno-suppressants)

Around 300,000 adult patients

in the U.S.

Dupixent® is developed in collaboration with Regeneron Pharmaceuticals, Inc. Dupixent® is an investigational agent under clinical development and its safety and efficacy has not been fully evaluated by any Regulatory Authority

®

● 235-300m people worldwide estimated to be affected by asthma(1)

● Chronic inflammatory disease leading to acute and chronic narrowing of the airway and increased mucus production

● Patients with asthma experience wheezing, shortness of breath, cough and chest tightness.

24

Moderate-to-Severe Asthma Negatively Impacts the Lives of Patients and Is Associated with High Burden to Society

24

(1) WHO, http://www.who.int/mediacentre/factsheets/fs307/en/ (2) Based on discussions with the U.S. FDA, the Phase 2b study may be considered one of two pivotal efficacy studies required for a potential

dupilumab biologics license application (BLA) in asthma. The Phase 3 clinical trial of dupilumab in patients with uncontrolled moderate-to-severe asthma, known as LIBERTY ASTHMA QUEST, will serve as the second required pivotal efficacy study.

A second pivotal dupilumab study in adults with uncontrolled moderate-to-severe asthma is ongoing(2)

25

64-75% Reduction in Exacerbations in Phase 2b in Moderate-to-Severe Asthma

0.0

0.2

0.4

0.6

0.8

1.0

1.2

High EosinophilsPopulation

Low EosinophilsPopulation

Overall population

Placebo200mg Q2W300mg Q2W

Dupilumab is developed in collaboration with Regeneron Pharmaceuticals, Inc. (1) Adjusted annualized severe exacerbation rates were derived from the 24-week treatment period During the treatment period, patients continue their stable medium- or high-dose inhaled corticosteroid and long-acting beta agonist (ICS/LABA) combination product Wenzel S et al. Lancet. April 26, 2016 http://dx.doi.org/10.1016/ S0140-6736(16)30307-5

-81%†

-71%*

-68%†

-60%*

* p<0.05 vs placebo

† p<0.01 vs placebo

‡ p<0.001 vs placebo

Annualized Rate of Severe Exacerbation Events(1)

-70%‡

-71%‡

Improvement in Lung Function in Phase IIb in Moderate-to-Severe Asthma

26

Dupilumab is developed in collaboration with Regeneron Pharmaceuticals, Inc. FEV1=forced expiratory volume over one second During the treatment period, patients continue their stable medium- or high-dose inhaled corticosteroid and long-acting beta agonist (ICS/LABA) combination product Wenzel S et al. Lancet. April 26, 2016 http://dx.doi.org/10.1016/ S0140-6736(16)30307-5

0

100

200

300

400

High EosinophilsPopulation

Low EosinophilsPopulation

Overall population

Placebo200mg Q2W300mg Q2W

12.8%

22.9%* 24.9%† mL

16.6%‡ 17.3%‡

7.0%

* p<0.05 vs placebo

† p<0.01 vs placebo

‡ p<0.001 vs placebo

Phase IIb - Mean Improvement in FEV1 at 24 Weeks (mL and % Change from Baseline)

13.4%† 12.6%†

4.7%

27

Safety Profile in Moderate-to-Severe Asthma

Placebo Dupilumab

59.2% 52.0%

Infections

Placebo Dupilumab

10.2% 4.0%

Severe AEs

Dupilumab Placebo

26.9%

12.7%

Injection site reactions

● Injection site reaction was the most common TEAE and more frequent with dupilumab ● Incidence of infections and Severe TEAEs was balanced across treatment groups ● Other common adverse events in the study included upper respiratory tract infection, headache,

nasopharyngitis and bronchitis

Phase IIb Study

Dupilumab is developed in collaboration with Regeneron Pharmaceuticals, Inc. Final 24wk safety results from all dupilumab dose cohorts in the Phase 2b study Wenzel S et al. Lancet. April 26, 2016 http://dx.doi.org/10.1016/ S0140-6736(16)30307-5

13.3% 5.7%

53.2%

Range in dupilumab

dose cohorts

28

Agenda

2016 Financial performance

Leading position in Rare Diseases

Rapidly growing Multiple Sclerosis portfolio

New Sanofi Genzyme Immunology franchise

Re-building a competitive position in Oncology

29

Re-Building a Competitive Position in Oncology

MoA: Mechanism of Action (1) HDeckert, et al. Clin Cancer Res 2014;20:4574–83. (2) ICARIA-MM: A phase 3 randomized, open-label, multicenter study comparing Isatuximab (SAR650984) in Combination with Pomalidomide And Low-

Dose Dexamethasone verRsus Pomalidomide and Low-Dose Dexamethasone In patients with refractory or relapsed and refractory Multiple Myeloma

Isatuximab (anti-CD38)

● Pivotal Phase 2/3 study in cutaneous squamous cell carcinoma ongoing

● Phase 2 study in basal cell carcinoma expected to start in H1 2017

● Start of Phase 2 study in non-small cell lung cancer planned for H1 2017

PD-1 (REGN2810)

Sanofi’s Antibody Drug Conjugates (ADCs) in Phase 1 complementary to our multi-specific antibody platform and IO strategy

● Product profile potentially differentiated ● Targets unique epitope with a distinct combination MoA(1)

● Phase 3 study in relapsed/refractory multiple myeloma initiated in December(2)

● Potential indications beyond multiple myeloma being explored

Expected Regulatory Decisions Q1 Q2 Q3 Q4 ● Dupixent®(1) in Atopic Dermatitis (U.S.) ● Kevzara® in Rheumatoid Arthritis (U.S.) ● Kevzara® in Rheumatoid Arthritis (EU) Expected Regulatory Submissions Q1 Q2 Q3 Q4 ● Kevzara® in Rheumatoid Arthritis (U.S.) ● Dupixent®(1) in Atopic Dermatitis (Japan) ● dupilumab in Asthma in Adult patients (U.S.) Expected Phase III / IIIb Topline Data Q1 Q2 Q3 Q4 ● patisiran in Familial amyloidotic polyneuropathy ● dupilumab in Asthma in Adult patients Expected Phase III Starts Q1 Q2 Q3 Q4 ● dupilumab in Asthma in patients aged 6-11 year-old ● fitusiran (ALN-AT3) in Hemophilia ● Dupixent®(1) AD in 6-11 and 12-17 year-old

30

2017 Will Be a Busy Year for Sanofi Genzyme

(1) The European Medicines Agency (EMA) and FDA have conditionally accepted Dupixent® as the trade name for dupilumab.